Exenatide Research

Belančić A, Antza C, Poutachidis A, Palaska S, Gkrinia EMM, Faour AK et al.

Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta-analysis (NMA) systemat...

Maheshwari D, Badgujar D, Kumar G, Sharma N

Peptide therapeutics are becoming an increasingly important class of pharmaceuticals due to their attractive therapeutic properties. However, their development remains challenging because of inherent structural complexity, requiring advanced analytical techniques. Peptide mapping is a key method ...

Huhulea EN, Frishman WH, Aronow WS

Tobacco use remains the leading preventable cause of death in the United States, with well-established links to cardiovascular morbidity and mortality. Despite the availability of pharmacologic and behavioral therapies, sustained smoking cessation remains a challenge for many individuals. This na...

Patil S, Jha N, Jha MK

Substance use disorders (SUDs) are widely prevalent and associated with high morbidity and mortality. Current treatments have limited efficacy and there are no United States Food and Drug Administration (FDA)-approved treatments for several SUDs (such as methamphetamine, cocaine, and cannabis use...

Nordell P, Jansson-Löfmark R, Gennemark P

Peptide-based therapeutics represent a rapidly expanding class of drugs. Endogenous peptides typically exhibit short elimination half-lives due to proteolytic cleavage and renal filtration. However, modifications such as amino acid substitutions and fatty-acid conjugation can significantly prolon...

Huang Y, Lin X, Deng M, Tang Y, Li S, Xu B et al.

The oral delivery of native glucagon like peptide-1 (GLP-1) using recombinant probiotics has shown hypoglycaemic effects and glucose tolerance improvement in diabetic mice. However, the pharmacological mechanisms remain incompletely understood. This study aimed to clarify whether GLP-1 analogues ...

Stefanou MI, Panagiotopoulos E, Tentolouris A, Theodorou A, Papagiannopoulou G, Athanasaki A et al.

Converging lines of preclinical evidence support the neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Parkinson's disease (PD). Nevertheless, results from randomized-controlled clinical trials (RCTs) remain conflicting.To assess the safety and efficacy of GLP...

Srisurapanont M, Suttajit S, Likhitsathian S, Suradom C, Maneeton B

ObjectiveThis systematic review and meta-analysis evaluated the efficacy, acceptability, and tolerability of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with severe mental illness (SMI).MethodsPubMed, Embase, the Cochrane Library, Google Scholar, and ClinicalTrials.gov wer...

Parikh M, MMath JP, Shen J, Kramer CK, Zinman B, Beaudry JL et al.

Prolonged exposure to hormonal therapy can affect endogenous hormone secretion. In type 2 diabetes (T2DM), glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly being administered in combination with therapies targeting additional hormones (including glucose-dependent insulinotropic ...

Santos P, Sá Filho AS, Aprigliano V, Duarte AG, Ribeiro NA, Lombardo KM et al.

Background/Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exhibit neuroprotective properties in preclinical models of Alzheimer's disease (AD), reducing amyloid accumulation, neuroinflammation, and insulin resistance within the brain. However, clinical evidence regarding their c...

Salmanoglu M, Ercan G, Genç HS, Gül SS, Aygün H

Background and Objectives: This study was designed to evaluate the potential cardioprotective effect of Exenatide against doxorubicin (DOX)-induced myocardial injury in rats by assessing scintigraphic alterations together with oxidative stress and inflammation. Materials and Methods: This study i...

Voros C, Chatzinikolaou F, Papapanagiotou I, Polykalas S, Mavrogianni D, Koulakmanidis AM et al.

Women of reproductive age, especially those with polycystic ovarian syndrome (PCOS), often use glucagon-like peptide-1 receptor agonists (GLP-1RAs) to improve their metabolic functions. A growing body of evidence suggests that GLP-1R signaling may directly affect ovarian physiology, influencing g...

Ailawadi S, Murphy JE, Storandt MH, Mahipal A

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have advanced the treatment of type 2 diabetes mellitus (T2DM), yet their association with cancer risk remains subject of ongoing research. Chronic pancreatitis (CP) is a well-established risk factor for pancreatic cancer, yet the ...

Singh R, Daniell H

Diabetes Mellitus is an epidemic affecting > 500 million, claiming 6-7 million lives annually. Chemically synthesised Glucagon-like peptide-1 receptor agonists (GLP-1RAs) containing artificial amino acids reduce haemoglobin A1c and obesity but are not yet affordable and require invasive...

Teil M, Huot P

An important part of the field of experimental pharmacology encompasses the study of the effects of molecules in animals. In the case of Parkinson's disease (PD), animal models have played an invaluable role in refining our understanding of the disease, in characterizing the effect of new compoun...

Kumar V, Sudha TYS, Bhattacharjee D, Mateen A, Mahato SK

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for type 2 diabetes mellitus (T2DM) and obesity, show promising potential as a novel treatment for depression, particularly in patients with comorbid metabolic disorders. This narrative review examines the bidirectional r...

Tumu S, Maram Reddy VY, Jayasuriya N, Ali M, Munir A, Malasevskaia I et al.

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms, including cognitive decline, which plays a significant role in its pathogenesis. This systematic review aimed to evaluate the efficacy of therapeutic strategies in reducing symptoms...

O'Mara A, Mody BP, Mammi M, Simjian T, Ghattas K, Kaliki S et al.

Currently, the cognitive impact of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remains unclear in non-diabetic patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), despite their widespread use for type 2 diabetes. This meta-analysis summarized cognitive outcomes f...

Riccioni G, Notarangelo C, Riccioni M, D'Orazio N

Cardiovascular diseases (CVDs) represent one of the leading causes of morbidity and mortality in patients with diabetes. However, a correct and effective glycaemic control obtained by pharmacologic interventions, such as the use the novel glucose-lowering agents, demonstrated efficacy in reducing...

Giugliano D, Longo M, Di Martino N, Scappaticcio L, Caruso P, Bellastella G et al.

The aim of this systematic review and meta-analysis was to evaluate the effect of GLP-1RAs on functional walking distance and the risk of major adverse limb events (MALE) or lower extremity amputation (LEA) in people with type 2 diabetes and peripheral artery disease (PAD).We searched many electr...